Peer-influenced content. Sources you trust. No registration required. This is HCN.

The New England Journal of MedicineAzacitidine and Venetoclax in Previously Untreated Acute Myeloid Leukemia

Overall survival was longer and the rate of remission was higher among patients who received azacitidine (Vidaza) with venetoclax (Venclexta) than among those who received azacitidine alone in previously untreated patients who were ineligible for intense chemotherapy. Compared to the control group, the venetoclax-azacitidine group had a greater incidence of febrile neutropenia.

The Healthcare Communications Network is owned and operated by IQVIA Inc.

Click below to leave this site and continue to IQVIA’s Privacy Choices form